MedPath
FDA Approval

Hextend

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Hospira, Inc.
DUNS: 141588017
Effective Date
February 15, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Hydroxyethyl Starch(6 g in 100 mL)

Registrants1

Companies and organizations registered with the FDA for this drug approval, including their contact information and regulatory details.

BioTime Inc.

781078977

Manufacturing Establishments2

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Hospira, Inc.

Hospira, Inc.

BioTime Inc.

093132819

Fresenius Kabi Austria GmbH

Hospira, Inc.

BioTime Inc.

303448575

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Hextend

Product Details

NDC Product Code
0409-1555
Application Number
BN200952
Marketing Category
NDA (C73594)
Route of Administration
INTRAVENOUS
Effective Date
February 15, 2023
Code: 875Y4127EAClass: ACTIBQuantity: 6 g in 100 mL
SODIUM CHLORIDEInactive
Code: 451W47IQ8XClass: IACT
POTASSIUM CHLORIDEInactive
Code: 660YQ98I10Class: IACT
SODIUM LACTATEInactive
Code: TU7HW0W0QTClass: IACT
CALCIUM CHLORIDEInactive
Code: M4I0D6VV5MClass: IACT
DEXTROSE MONOHYDRATEInactive
Code: LX22YL083GClass: IACT
WATERInactive
Code: 059QF0KO0RClass: IACT
MAGNESIUM CHLORIDEInactive
Code: 02F3473H9OClass: IACT
© Copyright 2025. All Rights Reserved by MedPath